COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,046 Articles (22,627 medRxiv, 8,419 bioRxiv)

Most recent first Previous |  Page 882: Articles 8811-8820  | Next

Post-acute symptoms, new onset diagnoses and health problems 6 to 12 months after SARS-CoV-2 infection: a nationwide questionnaire study in the adult Danish population
Sorensen, A. I. V., Spiliopoulos, L., Bager, P. M., Nielsen, N. M., Hansen, J. V., Koch, A., Meder, I. K., Ethelberg, S., Hviid, A.
10.1101/2022.02.27.22271328 — Posted: 2022-02-28 Discussion: Onsite
Genomic surveillance of SARS-CoV-2 in a university community: insights into tracking variants, transmission, and spread of Gamma (P.1) variant
Ciubotariu, I. I., Dorman, J., Perry, N. M., Gorenstein, L., Kattoor, J. J., Fola, A. A., Zine, A., Hendrix, G. K., Wilkes, R. P., Kitchen, A., Carpi, G.
10.1101/2022.02.25.22271521 — Posted: 2022-02-28
Comparison of Rapid Antigen Tests' Performance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study
Soni, A., Herbert, C., Filippaios, A., Broach, J., Colubri, A., Fahey, N., Woods, K., Nanavati, J., Wright, C., Orwig, T., Gilliam, K., Kheterpal, V., Suvarna, T., Nowak, C., Schrader, S., Lin, H., O'Connor, L., Pretz, C., Ayturk, D., Orvek, E., Flahive, J., Lazar, P., Shi, Q., Achenbach, C. J., Murphy, R. L., Robinson, M. L., Gibson, L., Stamegna, P., Hafer, N., Luzuriaga, K., Barton, B., Manabe, Y. C., McManus, D., RADx Clinical Studies Core Team, , Test Us At Home Investigators
10.1101/2022.02.27.22271090 — Posted: 2022-02-28 Discussion: Onsite
Design, Synthesis and Evaluation of Inhibitors of the SARS-CoV-2 nsp3 Macrodomain
Sherrill, L. M., Joya, E. E., Walker, A., Roy, A., Alhammad, Y. M., Atobatele, M., Wazir, S., Abbas, G., Keane, P., Zhuo, J., Leung, A., Johnson, D. K., Lehtio, L., Fehr, A., Ferraris, D. V.
10.1101/2022.02.27.482176 — Posted: 2022-02-28
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
Ohashi, H., Hishiki, T., Akazawa, D., Kim, K. S., Woo, J., Shionoya, K., Tsuchimoto, K., Iwanami, S., Moriyama, S., Kinoshita, H., Yamada, S., Kuroda, Y., Yamamoto, T., Kishida, N., Watanabe, S., Hasegawa, H., Ebihara, H., Suzuki, T., Maeda, K., Fukushi, S., Takahashi, Y., Iwami, S., Watashi, K.
10.1101/2022.02.27.482147 — Posted: 2022-02-28
An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques
Madden, P. J., Thomas, Y., Blair, R. V., Samer, S., Doyle, M., Midkiff, C. C., Becker, M. E., Arif, M. S., McRaven, M. D., Simons, L. M., Carias, A. M., Martinelli, E., Lorenzo-Redondo, R., Hultquist, J. F., Villinger, F. J., Veazey, R. S., Hope, T. J.
10.1101/2022.02.25.481974 — Posted: 2022-02-28
A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2
Priya, P., Basit, A., Bandyopadhyay, P.
10.1101/2022.02.27.482153 — Posted: 2022-02-28
Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3
Ma, H., Tseng, C.-T. K., Zong, H., Liao, Y., Ke, Y., Tang, H., Wang, L., Wang, Z., He, Y., Chang, Y., Wang, S., Drelich, A., Hsu, J., Tat, V., Yuan, Y., Wu, M., Liu, J., Yue, Y., Xu, W., Zhang, X., Wang, Z., Yang, L., Chen, H., Bian, Y., Zhang, B., Yin, H., Chen, Y., Zhang, E., Zhang, X., Gilly, J., Sun, T., Han, L., Xie, Y., Jiang, H., Zhu, J.
10.1101/2022.02.25.482049 — Posted: 2022-02-28
Drivers of adaptive evolution during chronic SARS-CoV-2 infections
Harari, S., Tahor, M., Rutsinsky, N., Meijer, S., Miller, D., Henig, O., Halutz, O., Levytskyi, K., Ben-Ami, R., Adler, A., Paran, Y., Stern, A.
10.1101/2022.02.17.22270829 — Posted: 2022-02-28
Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
Dorabawila, V., Hoefer, D., Bauer, U. E., Bassett, M., Lutterloh, E., Rosenberg, E.
10.1101/2022.02.25.22271454 — Posted: 2022-02-28 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).